Cost of implementing CAR-T activity and managing CAR-T patients: an exploratory study

• Egile Nagusiak: Maria Caterina Cavallo (Egilea), Marianna Cavazza (Egilea), Francesca Bonifazi (Egilea), Beatrice Casadei (Egilea), Ilaria Cutini (Egilea), Barbara Tonietti (Egilea), Riccardo Saccardi (Egilea), PierLuigi Zinzani (Egilea), Claudio Jommi (Egilea)
• Formatua: Liburua
• Argitaratua: BMC, 2024-01-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Abstract Background Chimeric antigen receptor T cells (CAR-T) represent an innovation but raise issues for healthcare payers because of the uncertainty on impact at market launch, high cost and important organisational impact. The literature has focused on their assessment, appraisal and market acce...